4 results on '"Achim H.-P. Krauss"'
Search Results
2. Antiglaucoma EP
- Author
-
David F, Woodward, Jenny W, Wang, W Daniel, Stamer, E, Lütjen-Drecoll, Achim H-P, Krauss, and Carol B, Toris
- Subjects
Drug Delivery Systems ,Animals ,Humans ,Glaucoma ,Receptors, Prostaglandin E, EP2 Subtype ,Antihypertensive Agents - Abstract
For2 decades, EP
- Published
- 2019
3. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models
- Author
-
Ennio Ongini, Achim H.-P. Krauss, Francesco Impagnatiello, Minerva R. Batugo, Ganesh Prasanna, Valentina Borghi, Carol B. Toris, and Elena Bastia
- Subjects
Male ,medicine.medical_specialty ,Intraocular pressure ,genetic structures ,Prostaglandin ,Ocular hypertension ,Pharmacology ,Nitric oxide ,Aqueous Humor ,chemistry.chemical_compound ,Ciliary body ,Dogs ,Tandem Mass Spectrometry ,Ophthalmology ,medicine ,Animals ,Nitric Oxide Donors ,Antihypertensive Agents ,Intraocular Pressure ,Bimatoprost ,business.industry ,Ciliary Body ,medicine.disease ,eye diseases ,Disease Models, Animal ,Macaca fascicularis ,medicine.anatomical_structure ,Prostaglandin F2alpha ,chemistry ,Ocular Hypertension ,sense organs ,Trabecular meshwork ,Rabbits ,business ,medicine.drug - Abstract
PURPOSE The prostaglandin F2alpha (PGF2α) analogue bimatoprost lowers intraocular pressure (IOP) by increasing uveoscleral outflow at doses shown to elicit redness of the eye. With the aim to enhance the IOP-lowering effect of bimatoprost we studied NCX 470 [(S,E)-1-((1R,2R,3S,5R)-2-((Z)-7-(ethylamino)-7-oxohept-2-enyl)-3,5-dihydroxycyclopentyl)-5-phenylpent-1-en-3-yl 6-(nitrooxy)hexanoate], a dual-acting compound combining bimatoprost with nitric oxide (NO) known to mainly act via relaxation of trabecular meshwork and Schlemm's canal. METHODS New Zealand white rabbits with transient hypertonic saline-induced IOP elevation (tOHT-rabbits), cynomolgus monkeys with laser-induced ocular hypertension (OHT-monkeys), and normotensive dogs (ONT-dogs) were used. The levels of NCX 470, bimatoprost, and bimatoprost acid were determined in aqueous humor (AH), cornea (CR), and iris/ciliary body (ICB) by liquid chromatography-mass spectrometry/mass (LC-MS/MS), while cGMP in AH and ICB was monitored using an enzyme immunoassay (EIA) kit in pigmented Dutch Belted rabbits. RESULTS NCX 470 (0.14%, 30 μL) lowered IOP in tOHT-rabbits with an E(max) of -7.2 ± 2.8 mm Hg at 90 minutes. Bimatoprost at equimolar dose (0.1%, 30 μL) was noneffective in this model. NCX 470 (0.042%, 30 μL) was more effective than equimolar (0.03%, 30 μL) bimatoprost in ONT-dogs (IOP change, -5.4 ± 0.7 and -3.4 ± 0.7 mm Hg, respectively, P < 0.05) and in OHT-monkeys (IOP change, -7.7 ± 1.4 and -4.8 ± 1.7 mm Hg, respectively, P < 0.05) at 18 hours post dosing. NCX 470 (0.042%, 30 μL) or bimatoprost (0.03%, 30 μL) resulted in similar bimatoprost acid exposure in AH, CR, and ICB while cGMP was significantly increased in AH and ICB at 18 and 24 hours after NCX 470 dosing. CONCLUSIONS NCX 470 lowers IOP more than equimolar bimatoprost in three animal models of glaucoma by activating PGF2α and NO/cGMP signaling pathways.
- Published
- 2015
4. Improvement of Outcome Measures of Dry Eye by a Novel Integrin Antagonist in the Murine Desiccating Stress Model
- Author
-
Johanna Tukler-Henriksson, Cintia S. de Paiva, Achim H.-P. Krauss, Flavia S. A. Pelegrino, Rosa M. Corrales, and Stephen C. Pflugfelder
- Subjects
Administration, Topical ,Integrin alpha4 ,Phenylalanine ,Integrin ,Anti-Inflammatory Agents ,Vascular Cell Adhesion Molecule-1 ,Integrin alpha4beta1 ,CD49d ,Collagen receptor ,Cornea ,Mice ,Piperidines ,Cell Adhesion ,Leukocytes ,Animals ,Organic Chemicals ,Cells, Cultured ,Integrin alpha Chains ,biology ,Cell adhesion molecule ,CD29 ,Dendritic Cells ,Flow Cytometry ,eye diseases ,Mice, Inbred C57BL ,Disease Models, Animal ,Integrin alpha M ,Immunology ,biology.protein ,Eye disorder ,Dry Eye Syndromes ,Female ,Biomarkers - Abstract
Dry eye disease (DED) is one of the most common and discomforting eye disorders. It has been defined as a multifactorial ocular surface disease more prevalent in women and the elderly. Dry eye disease is associated with symptoms of discomfort, visual disturbance, tear film instability, and inflammation of the ocular surface leading to potential damage to the ocular surface tissues.1 The proinflammatory milieu is characterized by increased levels of cytokines and chemokines in the tear film, cornea, and conjunctiva, and increased autoreactive T-cell infiltration of the conjunctival epithelium and sometimes lacrimal gland2–4; reviewed by Stern et al.5,6 Alteration of the tear film composition (mucins, lipids, proteins) and decreased volume lead to tear film abnormalities that contribute to the disease cycle. Subjecting mice to a controlled environment of desiccating stress results in ocular surface pathology reminiscent of human DED in patients in many respects.3,7–9 As of today, this model represents the best characterized animal model to study DED. Integrins are heterodimeric glycoproteins consisting of one α- and one β-subunit. Expressed on the cell surface of leukocytes, integrins have a role in their recruitment to sites of inflammation. The association of a specific α- and β-subunit determines the ligand specificity of the integrin. The α4 integrin subunit (CD49d) is a constituent of Very Late Antigen-4 (VLA-4, integrin a4b1, CD49d/CD29), and α4β7 (CD49d/CD103). In the case of integrin α4β1 the corresponding ligands are the immunoglobulin superfamily adhesion molecule vascular cell adhesion molecule 1 (VCAM-1) on vascular endothelial cells and the extracellular matrix glycoprotein fibronectin, which are responsible for the homing, trafficking, differentiation, priming, activation, and survival of integrin α4β1 expressing cells. Integrin α4β1 is expressed on lymphocytes, monocytes, macrophages, NK cells, and eosinophils. Integrin α4β7 and its corresponding ligand Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM) selectively regulate leukocyte trafficking to the gut and consequently are unlikely to be involved in the effects described herein. Natalizumab, an antibody directed against the α4 integrin subunit, has been shown to profoundly inhibit inflammation and improve clinical outcomes in multiple sclerosis10 and Crohn's disease,11 which also are T-cell–mediated diseases. Lifitegrast, a small molecule antagonist, directed against a different adhesion molecule (LFA-1, integrin αLβ2), has been shown to reduce corneal staining and improve symptoms when delivered topically to dry eye patients.12 Furthermore, a specific antagonist to integrin α4β1, BIO-8809, had been shown to decrease corneal fluorescein staining, conjunctival T-cell infiltrates, and TNFα expression in cornea and conjunctiva in a murine dry eye model.13 Taken together these considerations provided a rationale for further exploring the blockade of integrin α4 in an animal model of DED. In the current study, we tested the hypothesis using {"type":"entrez-nucleotide","attrs":{"text":"GW559090","term_id":"289141609","term_text":"GW559090"}}GW559090, a potent integrin α4 antagonist that previously had been clinically investigated in asthma patients by the oral inhalation route.14
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.